Our Pricing

Wegovy vs Mounjaro: Which Weight Loss Injection Is Best for You?

When comparing Wegovy vs Mounjaro, both GLP-1 receptor agonist injections offer proven weight loss results, but they differ in mechanism, efficacy, and cost. Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, whilst Wegovy (semaglutide) targets GLP-1 alone—a distinction that influences their comparative effectiveness. As a UK-registered pharmacy with transparent pricing and expert clinical support, Cured Pharmacy helps patients navigate this choice with confidence.

How Wegovy vs Mounjaro Work Differently in Your Body

Understanding the pharmacological difference between Wegovy vs Mounjaro is essential for informed decision-making. Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a natural gut hormone to reduce appetite, slow gastric emptying, and improve blood sugar regulation [1]. Mounjaro, however, contains tirzepatide—a dual GIP/GLP-1 receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways simultaneously [2].

This dual-action mechanism gives Mounjaro a theoretical advantage in metabolic impact. Clinical trials suggest the additional GIP receptor activation may enhance insulin secretion, improve lipid metabolism, and potentially amplify weight loss compared to GLP-1 monotherapy [2]. Both medications are administered as once-weekly subcutaneous injections and require gradual dose escalation to minimise gastrointestinal side effects, which are common to the GLP-1 class.

Wegovy vs Mounjaro Weight Loss Results: What Clinical Trials Show

Head-to-head data on Wegovy vs Mounjaro efficacy comes primarily from the SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1mg (the dose used in Ozempic, not Wegovy's higher 2.4mg maintenance dose) [3]. In that study, participants on tirzepatide 15mg lost an average of 12.4kg over 40 weeks, compared to 6.2kg on semaglutide 1mg—a statistically significant difference.

However, when comparing maximum approved doses—Wegovy 2.4mg vs Mounjaro 15mg—the gap narrows. The STEP 1 trial demonstrated that Wegovy 2.4mg produced an average weight loss of 14.9% of body weight over 68 weeks in adults without diabetes [1]. The SURMOUNT-1 trial showed Mounjaro 15mg achieved an average of 20.9% body weight reduction over 72 weeks [4]. Both medications outperform older weight loss treatments significantly, but Mounjaro appears to deliver greater average weight loss at maximum doses, subject to individual response and tolerability.

Real-World Weight Loss Expectations for Wegovy vs Mounjaro

In clinical practice, results vary widely based on adherence, lifestyle factors, starting BMI, and metabolic health. Most patients on either Wegovy or Mounjaro begin noticing appetite suppression within the first two weeks, with measurable weight loss typically evident by week four. Optimal results require staying on treatment for at least six months, combined with a reduced-calorie diet and increased physical activity. Neither medication is a standalone solution—they are adjuncts to comprehensive lifestyle modification.

Side Effects: Wegovy vs Mounjaro Tolerability and Safety

The side effect profiles of Wegovy vs Mounjaro are broadly similar, as both belong to the GLP-1 receptor agonist class. The most common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation [1][2]. These gastrointestinal symptoms are typically mild to moderate and diminish over time as the body adjusts.

Some trial data suggest Mounjaro may cause slightly higher rates of nausea and vomiting at higher doses compared to Wegovy, though individual tolerability varies [3][4]. Both medications carry a boxed warning in the US regarding thyroid C-cell tumours observed in rodent studies—though no causal link has been established in humans, neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Rare but serious risks include pancreatitis, gallbladder disease, and hypoglycaemia (especially when combined with insulin or sulfonylureas). All patients require clinical assessment by a UK-registered prescriber before starting either treatment, with ongoing monitoring for adverse effects and treatment response.

Wegovy vs Mounjaro UK Price Comparison and Availability

Cost is a critical factor when choosing between Wegovy vs Mounjaro, as neither is routinely available on NHS prescription for weight loss alone—most patients access them privately. At Cured Pharmacy, Wegovy starts from £124.99 per injection pen, whilst Mounjaro starts from £124.99, reflecting differences in manufacturing, licensing, and market positioning [5].

Supply availability fluctuates across the UK due to high demand and manufacturing constraints. Wegovy experienced significant shortages throughout 2023 and early 2024, though supply has stabilised. Mounjaro, approved more recently for weight management in the UK, has generally maintained better stock levels. Cured Pharmacy provides transparent upfront pricing and real-time stock visibility, ensuring patients can make informed decisions without hidden consultation fees.

Insurance and NHS Coverage for Wegovy vs Mounjaro

NHS England has restricted access to both medications due to budget constraints and supply issues. NICE guidelines recommend semaglutide 2.4mg (Wegovy) for weight management in adults with a BMI ≥35 (or ≥32.5 in certain ethnic groups) with at least one weight-related comorbidity, but local ICBs may not commission it. Tirzepatide (Mounjaro) received NICE approval for weight management in early 2024 under similar criteria, though rollout remains limited. Most UK patients currently access these treatments privately, with costs ranging from approximately £124.99 to £124.99+ per month depending on dose and provider.

Dosing and Administration: Wegovy vs Mounjaro Schedules

Both Wegovy vs Mounjaro require gradual dose titration to improve gastrointestinal tolerability. Wegovy starts at 0.25mg weekly for four weeks, increasing monthly through 0.5mg, 1mg, 1.7mg, and finally 2.4mg maintenance dose [1]. Mounjaro begins at 2.5mg weekly for four weeks, then escalates to 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg maximum [2].

Each medication is supplied in pre-filled, single-use injection pens designed for subcutaneous self-administration into the abdomen, thigh, or upper arm. Patients rotate injection sites weekly to minimise local reactions. Missed doses should be taken within five days for Wegovy or within four days for Mounjaro; otherwise, skip the missed dose and resume the regular schedule. Both medications require refrigeration before first use, though Wegovy pens can be stored at room temperature for up to 28 days once in use.

Who Should Choose Wegovy vs Mounjaro? Clinical Considerations

Deciding between Wegovy vs Mounjaro depends on individual clinical factors, cost sensitivity, and treatment goals. Mounjaro may be preferable for patients seeking maximum average weight loss and who can tolerate higher upfront costs, particularly those with type 2 diabetes (as tirzepatide also has robust glycaemic benefits) [4]. Wegovy offers a proven track record, broader real-world experience, and lower cost per dose, making it an excellent first-line choice for many patients.

Neither medication is suitable for patients with a history of medullary thyroid carcinoma, MEN 2 syndrome, or severe gastrointestinal disease. Pregnant or breastfeeding women should not use either treatment. Patients with a history of pancreatitis, gallstones, or diabetic retinopathy require careful risk-benefit assessment. At Cured Pharmacy, every prescription undergoes clinical review by our UK-registered prescribers, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), ensuring safe, personalised treatment decisions.

Ultimately, the 'best' choice between Wegovy vs Mounjaro is the one you can afford, tolerate, and sustain long-term. Both are highly effective tools when combined with lifestyle modification, and switching between them is possible if initial results or tolerability are suboptimal.

How to Get Started with Wegovy vs Mounjaro at Cured Pharmacy

Starting treatment is straightforward: complete a free online consultation (under three minutes) on the Cured Pharmacy website, where a UK prescriber reviews your medical history, current medications, and weight loss goals. If clinically appropriate, your prescription is issued and dispensed from our GPhC-registered pharmacy (9012511), with discreet next-day delivery across the UK. New patients Save £20 off their first order with code Weightlossnew, making Wegovy available from £124.99—the cheapest UK price for genuine, licensed medication with full clinical support.

Scientific References

1. Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Frías, J. P., et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes: The SURPASS-2 trial. Diabetes Care, 44(11), 2523-2532. [accessed 15 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.